Reviewing BridgeBio Pharma Inc. (BBIO)’s and Novan Inc. (NASDAQ:NOVN)’s results

Both BridgeBio Pharma Inc. (NASDAQ:BBIO) and Novan Inc. (NASDAQ:NOVN) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BridgeBio Pharma Inc. 35 0.00 78.05M -4.73 0.00
Novan Inc. 2 0.00 18.32M -1.01 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of BridgeBio Pharma Inc. and Novan Inc.


Table 2 represents BridgeBio Pharma Inc. (NASDAQ:BBIO) and Novan Inc. (NASDAQ:NOVN)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
BridgeBio Pharma Inc. 221,481,271.28% 0% 0%
Novan Inc. 888,070,192.45% 233.9% -79.5%


The Current Ratio and a Quick Ratio of BridgeBio Pharma Inc. are 14 and 14. Competitively, Novan Inc. has 1.3 and 1.3 for Current and Quick Ratio. BridgeBio Pharma Inc.’s better ability to pay short and long-term obligations than Novan Inc.

Analyst Ratings

BridgeBio Pharma Inc. and Novan Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BridgeBio Pharma Inc. 0 0 0 0.00
Novan Inc. 0 0 1 3.00

On the other hand, Novan Inc.’s potential upside is 130.77% and its average target price is $1.5.

Insider & Institutional Ownership

The shares of both BridgeBio Pharma Inc. and Novan Inc. are owned by institutional investors at 89% and 5.6% respectively. Insiders held 9% of BridgeBio Pharma Inc. shares. Comparatively, 35.49% are Novan Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BridgeBio Pharma Inc. 13.86% 49.01% 16.47% 0% 0% 19.85%
Novan Inc. 8.04% 0% -20.07% -15.02% 62.26% 159.04%

For the past year BridgeBio Pharma Inc. was less bullish than Novan Inc.


Novan Inc. beats on 6 of the 10 factors BridgeBio Pharma Inc.

Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The companyÂ’s product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. The company has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.